143 related articles for article (PubMed ID: 35264729)
1. A cross-species spatiotemporal proteomic analysis identifies UBE3A-dependent signaling pathways and targets.
Pandya NJ; Meier S; Tyanova S; Terrigno M; Wang C; Punt AM; Mientjes EJ; Vautheny A; Distel B; Kremer T; Elgersma Y; Jagasia R
Mol Psychiatry; 2022 May; 27(5):2590-2601. PubMed ID: 35264729
[TBL] [Abstract][Full Text] [Related]
2. Adult
Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
[TBL] [Abstract][Full Text] [Related]
3. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
Elgersma Y; Sonzogni M
Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
[TBL] [Abstract][Full Text] [Related]
4. Towards an understanding of Angelman syndrome in mice studies.
Yang X
J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793
[TBL] [Abstract][Full Text] [Related]
5. Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways.
Lopez SJ; Laufer BI; Beitnere U; Berg EL; Silverman JL; O'Geen H; Segal DJ; LaSalle JM
Hum Mol Genet; 2019 Nov; 28(22):3842-3852. PubMed ID: 31625566
[TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic approaches for Angelman syndrome.
Bi X; Sun J; Ji AX; Baudry M
Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
[TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome.
Ramirez J; Lectez B; Osinalde N; Sivá M; Elu N; Aloria K; Procházková M; Perez C; Martínez-Hernández J; Barrio R; Šašková KG; Arizmendi JM; Mayor U
Hum Mol Genet; 2018 Jun; 27(11):1955-1971. PubMed ID: 29788202
[TBL] [Abstract][Full Text] [Related]
8. HAP1 is an in vivo UBE3A target that augments autophagy in a mouse model of Angelman syndrome.
Wang T; Wang J; Wang J; Mao L; Tang B; Vanderklish PW; Liao X; Xiong ZQ; Liao L
Neurobiol Dis; 2019 Dec; 132():104585. PubMed ID: 31445164
[TBL] [Abstract][Full Text] [Related]
9. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
[TBL] [Abstract][Full Text] [Related]
10. JNK signaling activation in the Ube3a maternal deficient mouse model: its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
Musi CA; Agrò G; Buccarello L; Camuso S; Borsello T
Neurobiol Dis; 2020 Jul; 140():104812. PubMed ID: 32087286
[TBL] [Abstract][Full Text] [Related]
11. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
[TBL] [Abstract][Full Text] [Related]
12. Recovery of Angelman syndrome rat deficits with UBE3A protein supplementation.
Dodge A; Morrill NK; Weeber EJ; Nash KR
Mol Cell Neurosci; 2022 May; 120():103724. PubMed ID: 35367589
[TBL] [Abstract][Full Text] [Related]
13. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
14.
Wallace ML; van Woerden GM; Elgersma Y; Smith SL; Philpot BD
J Neurophysiol; 2017 Jul; 118(1):634-646. PubMed ID: 28468997
[TBL] [Abstract][Full Text] [Related]
15. Maternal Loss of Ube3a Impairs Experience-Driven Dendritic Spine Maintenance in the Developing Visual Cortex.
Kim H; Kunz PA; Mooney R; Philpot BD; Smith SL
J Neurosci; 2016 Apr; 36(17):4888-94. PubMed ID: 27122043
[TBL] [Abstract][Full Text] [Related]
16. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
17. UBE3A regulates the transcription of IRF, an antiviral immunity.
Furumai R; Tamada K; Liu X; Takumi T
Hum Mol Genet; 2019 Jun; 28(12):1947-1958. PubMed ID: 30690483
[TBL] [Abstract][Full Text] [Related]
18. Angelman Syndrome Protein Ube3a Regulates Synaptic Growth and Endocytosis by Inhibiting BMP Signaling in Drosophila.
Li W; Yao A; Zhi H; Kaur K; Zhu YC; Jia M; Zhao H; Wang Q; Jin S; Zhao G; Xiong ZQ; Zhang YQ
PLoS Genet; 2016 May; 12(5):e1006062. PubMed ID: 27232889
[TBL] [Abstract][Full Text] [Related]
19. Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome.
Gustin RM; Bichell TJ; Bubser M; Daily J; Filonova I; Mrelashvili D; Deutch AY; Colbran RJ; Weeber EJ; Haas KF
Neurobiol Dis; 2010 Sep; 39(3):283-91. PubMed ID: 20423730
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model.
Milazzo C; Mientjes EJ; Wallaard I; Rasmussen SV; Erichsen KD; Kakunuri T; van der Sman ASE; Kremer T; Miller MT; Hoener MC; Elgersma Y
JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34369389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
